



IFW

Docket 17630 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Olejnik et al
Customer No.: 051957
Serial No.: 10/574,523

Examiner: Not known

Group Art Unit: Not known

Filed: March 30, 2006

For: PHARMACEUTICAL
COMPOSITIONS COMPRISING
ALPHA-2-ADRENERGICS AND
TREFOIL FACTOR FAMILY PEPTIDES

INFORMATION DISCLOSURE STATEMENT

Mailstop: Information Disclosure Statement
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant provides with regard to the above-identified patent application entitled PHARMACEUTICAL COMPOSITIONS COMPRISING ALPHA-2-ADRENERGICS AND TREFOIL FACTOR FAMILY PEPTIDES, one copy of documents of which he is aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 2 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material




documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date:

5/5/06



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF FIRST CLASS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date 5/5/06, in an envelope as "First Class Mail Post Office to Addressee" addressed to Attn: Information Disclosure Statement: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Name of person mailing paper

Date:

5/5/06


Signature of person signing paper

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17630(AP)	SERIAL NO.: 10/574,523
APPLICANT: Olejnik	TITLE: PHARMACEUTICAL COMPOSITIONS COMPRISING ALPHA-2-ADRENERGICS AND TREFOIL FACTOR FAMILY PEPTIDES
FILING DATE: March 30, 2006	GROUP: Not known

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	60/509,955	10/8/2003	Olejnik et al			
	AB	5,703,077	12/20/1997	Burke et al			
	AC	3,890,319	6/17/1975	Danielwicz			
	AD	10/153,328	5/21/2002	Chow et al			
	AE	6,525,018	2/25/2003	Podolsky			
	AF	6,063,755	5/16/2000	Podolsky			
	AG	6,221,840	3/24/2001	Podolsky			
	AH	6,316,218	11/13/2001	Podolsky			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	2004/027914	8/26/2004	PCT			
	BB	WO 92/00073	1/9/1992	PCT			
	BC	1499485	2/1/1978	British			
	BD	WO 02102403	12/27/2002	PCT			
	BE	WO 02085402	10/31/2002	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

CA	Ruffolo, "α-Adrenoreceptors:Molecular Biology, Biochemistry and Pharmacology"; 1991
CB	Hauser et al, "hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus", Proc. Natl. Acad. Sci USA, Aug. 1993, Vol. 90, pp. 6961-6965
CC	Babyatsky et al, "Oral Trefoil Peptides Protect Against Ethanol- and Indomethacin-Induced Gastric Injury in Rats", Gastroenterology, 1996, Vol. 110, pp. 489-497
CD	Goke et al, "Trefoil Peptides Promote Restituion of Wounded Corneal Epithelial CellsExperimental Cell Research, 2001, Vol. 264, pages 337-344
CE	Playford, "Trefoil peptides: what are they and what do they do?",Journal of the Royal College of Physicians of London, Vol. 31, Jan./Feb. 1997, pp. 37-41
CF	Allen et al, "The Mucus Barrier", J. Clin. Gastroenteral; 10 (Suppl 1): S93-S98,1988
CG	Ligumsky et al, "Sucralfate Protection Against Gastrointestinal Damage: Possible Role of Prostanoids", Isr J Med Sci , 1986, Vol. 22: pp. 801-806
CH	Dignass et al, "Trefoil Peptides Promote Epithelial Migration through a Transforming Growth Factor β-independent Pathway", J. Clin. Invest., Vol. 94, pp 376-383
CI	Tabor et al, "Surface Forces and Surface Interactions", J. Colloid Interface Sci., Vol. 58: 1,Jan.1977, pp 1-12
CJ	Good, "Surface Free Energy of Solids and Liquids: Thermodynamics, Molecular Forces, and Structure", J. Colloid Interface Sci., 1977, Vol. 59:398-419

EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17630(AP)	SERIAL NO.: 10/574,523
APPLICANT: Olejnik	TITLE: PHARMACEUTICAL COMPOSITIONS COMPRISING ALPHA-2-ADRENERGICS AND TREFOIL FACTOR FAMILY PEPTIDES
FILING DATE: March 30, 2006	GROUP: Not known

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

	CK	Paulsen et al, "TFF Peptides in the Human Efferent Tear Ducts", Invest Ophthalmol Vis Sci 2002 Nov; 43(11): pp. 3359-3364
	CL	Thim et al, "Effect of trefoil factors on the viscoelastic properties of mucus gels", Eur J. Clin Invest 2002 Jul; 32(7): 519-527 (Abstract)

EXAMINER _____ **DATE CONSIDERED** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.